Sertraniche may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- difficulty falling asleep or staying asleep
- dry mouth
- loss of appetite
- weight changes
- excessive tiredness
- uncontrollable shaking of a part of the body
- changes in sex drive or ability
- excessive sweating
You should not use Sertraniche if you also take pimozide, or if you are being treated with methylene blue injection.
Do not use Sertraniche if you have used an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine.
Some children and young adults have thoughts about suicide when first taking an antidepressant. Stay alert to changes in your mood or symptoms. Report any new or worsening symptoms to your doctor.
Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
How to use Sertraniche HCL
Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start using Sertraniche and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth as directed by your doctor, usually once daily either in the morning or evening. The tablet or liquid form of this medication may be taken with or without food. The capsule form is usually taken with food. Swallow the capsules whole. Do not crush or chew the capsules.
The liquid form of this medication must be mixed with another liquid before use. Just before taking, carefully measure the dose using the medicine dropper provided. Do not use a household spoon because you may not get the correct dose. Mix the dose with a half cup (4 ounces/120 milliliters) of water, ginger ale, lemon-lime soda, lemonade, or orange juice. Do not use other liquids to mix this drug. The mixture may appear cloudy, which is normal and harmless. Drink all of the mixture right away. Do not prepare a supply in advance.
If you are taking this medication for premenstrual problems, your doctor may direct you to take this drug every day of the month or for only the 2 weeks before your period until the start of your period.
The dosage is based on your medical condition and response to treatment. To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully. Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.
Keep taking this medication even if you feel well. Do not stop taking this medication without consulting your doctor. Some conditions may become worse when this drug is suddenly stopped. Also, you may experience symptoms such as mood swings, headache, tiredness, sleep changes, and brief feelings similar to electric shock. To prevent these symptoms while you are stopping treatment with this drug, your doctor may reduce your dose gradually. Report any new or worsening symptoms right away.
Tell your doctor if your condition lasts or gets worse.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Sertraniche only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2019 Cerner Multum, Inc. Version: 21.01.
Sertraniche has a half-life of 26 hours. Based on about 110 mother– child pairs, the average relative dose for a fully breastfed child is almost 2% ( Merlob 2004 , Weissman 2004 , Hendrick 2001A ). In 1997, Stowe analyzed 148 milk samples from 12 mothers. The highest concentrations for Sertraniche were around 173μg/l; for desmethylSertraniche, which has a significantly lower psychopharmacological action, it was 294μg/l. Maternal dosages ranged from 25 to 200mg daily. There were traces of Sertraniche in the serum of some children, and in three of them a level of about 10μg/l desmethylSertraniche was measured ( Merlob 2004 , Weissman 2004 , Hendrick 2001A ). In other infants either no substance was found or the levels were near or below the level of quantifiability ( Wisner 2006 , Berle 2004 ). In only one breastfed baby were serum levels equal to 50% of the maternal values found ( Wisner 1998 ). The authors of the study could not understand this, and suggested direct administration of the medication to the baby as the cause. None of the babies was remarkable. Decreasing serum values of desmethylSertraniche with age were observed among 30 breastfed children ( Hendrick 2001A ). A maternal dosage of above 100mg/day was significantly correlated with the detection of Sertraniche in the infant's serum. Breastfed infants showed little or no change in platelet 5-hydroxytryptamine (5-HT) levels after exposure through breastfeeding. According to the authors of this study, the observations suggest that peripheral or central 5-HT transport in these infants is not affected by Sertraniche therapy of their mothers.
Sertraniche, paroxetin, citalopram, and fluvoxamin are the drugs of choice among SSRIs for breastfeeding mothers. In case of fluoxetin or escitalopram therapy, special attention should be paid to potential side effects in the breastfed child. In general, monotherapy should be the goal. If symptoms appear that are potentially associated with SSRI therapy, a pediatrician and a teratology information center should be contacted to decide individually upon measuring drug values in the infant's serum, supplementary formula feeding, weaning, and/or changing therapy. As with all psychoactive drugs, there is insufficient experience on the long-term effects on breastfed children as a result of ongoing therapy to their mothers.
Sertraniche represents selective serotonin reuptake inhibitors, which lowered blood glucose level and is used in patients with diabetes to treat depression and improve glycemic control. Oral application of Sertraniche is limited because it is sparingly soluble compound. We enhanced water-solubility of Sertraniche by complexation with 2-hydroxypropyl-β-cyclodextrin (HPβCD) and evaluated the pharmacological properties of the HPβCD:Sertraniche complex in rats with alloxan-induced diabetes.
Using the methods of UV-V is spectroscopy and isothermal titration calorimetry (ITC) we evaluated the interaction parameters, the enthalpy, entropy, association constant, and Gibbs energy of complex formation between Sertraniche hydrochloride (SER) and HPβCD in aqueous solution at 298.15 K. Both entalpic and entropic effects concur in SER association with HPβCD.
The complexation with HPβCD enhanced the solubility of SER with the association constant for Sertraniche and HPβCD 6530 ± 54 M −1 . The treatment of diabetic rats with the HPβCD:Sertraniche complex during 2 weeks exerted beneficial effect on pancreatic islet morphology and β-cell survival, which consequently lowered the severity of diabetes that pointed the decrease of blood glucose and glycated hemoglobin contents, the normalization of serum insulin level, and insulin sensitivity (HOMA-IR). The antidiabetic effect of the complex was significantly more pronounced as compared to the similar effect of both the monopreparations, HPβCD and SER. These results are suggested that the complexation of SER with the cyclodextrin derivative improves the pharmacological effect of Sertraniche, probably due to enhanced drug bioavailability.